© The Canadian Journal of Urology™; 21(Supplement 2); June 2014
86. Fonseca V, Jawa A, Endothelial and erectile dysfunction,
diabetes mellitus, and the metabolic syndrome: Common
pathways and treatments?
Am J Cardiol
2005;96(12B):13-18.
87. Vinik A, Richardson D. Erectile dysfunction in diabetes.
Diabetes Rev
1998;6:16-33.
88. Fedele D, Coscelli C, Santeusanio F et al for the Gruppo Italiano
Studio Deficit Erecttile nei Diabetici. Erectile dysfunction in
diabetic subjects in Italy.
Diabetes Care
1998;21(11):1973-1977.
89. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M,
Engelmann U. Epidemiology of erectile dysfunction:
results of the ‘Cologne Male Survey’.
Int J Imp Res
2000;12(6):
305-311.
90. Bacon CG, Hu FB, Giovannucci E, Glasser DB, MittlemanMA,
RimmEB. Association and type and duration of diabetes with
erectile dysfunction in a large cohort of men.
Diabetes Care
2002;
25(8):1458-1463.
91. Rhoden EL, Ribeiro EP, Riedner CE, Teloken C, Souto CA.
Glycosolated hemoglobin levels and the severity of erectile
function in diabetic men.
BJU Int
2005;95(4):615-617.
92. Gazzaruso C, Pujia A, Solerte SB et al. Erectile dysfunction
and angiographic extent of coronary artery disease in type II
diabetic patients.
In J Impot Res
2006;18(3):311-315.
93. Naya M, Tsukamoto T, Morita K et al. Plasma interleukin-6
and tumor necrosis factor-alpha can predict coronary
endothelial dysfunction in hypertensive patients.
Hypertens Res
2007;30(6):541-548.
94. Vlachopoulos C, Aznaouridis K, Ioakeimidis N et al.
Unfavourable endothelial and inflammatory state in erectile
dysfunction patients with or without coronary artery disease.
Eur Heart J
2006; 27(22):2640-2648.
95. Giugliano F, Esposito K, Di Palo C et al. Erectile dysfunction
associates with endothelial dysfunction and raised
proinflammatory cytokine levels in obese men.
J Endocrinol
Invest
2004;27(7):665-669.
96. Pearson TA, Mensah GA, Alexander RW et al. Markers of
inflammation and cardiovascular disease: application to
clinical and public health practice: A statement for healthcare
professionals from the Centers for Disease Control and
PreventionandtheAmericanHeartAssociation.
Circulation
2003;
107(3):499-511.
97. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to
prevent vascular events in men and women with elevated
C-reactive protein.
N Engl J Med
2008;359(21):2195-2207.
98. Weeks GR, Gambescia N. Erectile dysfunction: integrating
couples therapy, sex therapy, and medical treatment. New
York, WW Norton and Co. 2000:43-44.
99. Mosher D. Sex guilt and sexmyths in college men andwomen.
J Sex Res
1979;15(3):224-234.
100. Blumstein P, Schwartz, P. “American Couples: money, work,
and sex.” New York: William Morrow, 1983.
101. Sprecher S,McKinney, K. “Sexuality.”NewburyPark, CA: Sage,
1993.
102. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for
erectile dysfunction in the US.
Am J Med
2007;120(2):151-157.
103. Hambrecht R, Wolf A, Gielen S et al. Effect of exercise on
coronary endothelial function in patients with coronary artery
disease.
New Eng J Med
2000;342(7):454-460.
104. Gokce N, Vita JA, Bader DS et al. Effect of exercise on upper
and lower extremity endothelial function in patients with
coronary artery disease.
Am J Cardiol
2002;90(2):124-132.
105. Edwards DG, Schofield RS, Lennon SL et al. Effect of exercise
training on endothelial function in men with coronary artery
disease.
Am J Cardiol
2004;93(5):617-620.
106. Moore BE, RothschildAJ. Treatment of antidepressant-induced
sexual dysfunction.
Hosp Pract
1999;34(1):89-91,95-96.
107. Sadovsky R. Selecting patients appropriate for treatment.
J Fam Pract
2005;Suppl 5-14.
108. Data on File, IMS, Eli Lilly and Company 2007.
109. Bosshardt RJ, Farwerk R, Sikora R, SohnM, Jakse G. Objective
measurement of the effectiveness, therapeutic success, and
dynamic mechanisms of the vacuum device.
Br J Urol
1995;
75(6):786-791.
110. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric
oxide as a mediator of relaxation of the corpus cavernosum in
response to nonadrenergic, noncholinergic neurotransmission.
New Engl J Med
1992;326(2):90-94.
111. Helstrom WJG. Management recommendations for family
physicians.
J Fam Pract
2005 Suppl:32-40.
112. Jiann BP, Yu CC, Su CC, Tsai JY. Complaince of sildenafil
treatment for erectile dysfcutnion and factors affecting it.
Int J Impot Res
2006;18(2):146-149.
113. Vickers MA, Satyanarayana R. Phosphosdiesterase type 5
inihibotrs for the treatment of erectile dysfunction in patients
with diabetes mellitus.
Int J Impot Res
2002:14(6):466-471.
114. Montorsi F, Burnett AL. Erectile dysfunction after radical
prostatectomy.
BJU Int
2004;93(1):1-2.
115. Carson CC, Lue TF. Phosphodiesterase type 5 inihibotrs for
erectile dysfunction.
BJU Int
2005;96(3):257-280.
116. Nusbaum MR. Therapeutic options for patients returning to
sexual activity.
J AmOsteopath Assoc
2004:104(3 suppl 4):S2-S5.
38
Miner ET AL.
